| Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data CR Lee, JA Goldstein, JA Pieper Pharmacogenetics and genomics 12 (3), 251-263, 2002 | 911 | 2002 |
| Warp: an integrated solution of high-speed parallel computing S Borkar, R Cohn, G Cox, S Gleason, T Gross, HT Kung, M Lam, B Moore, ... Conference on High Performance Networking and Computing: Proceedings of the …, 1988 | 525 | 1988 |
| Clinical pharmacokinetics of fluvastatin CD Scripture, JA Pieper Clinical pharmacokinetics 40, 263-281, 2001 | 192 | 2001 |
| Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans CR Lee, JA Pieper, AL Hinderliter, RF Frye, JA Blaisdell, JA Goldstein The Journal of Clinical Pharmacology 43 (1), 84-91, 2003 | 138 | 2003 |
| Optimal management of amiodarone therapy: efficacy and side effects D Hilleman, MA Miller, R Parker, P Doering, JA Pieper Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18 (6P2 …, 1998 | 133 | 1998 |
| Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers KM Williamson, JH Patterson, RH McQueen, KF Adams Jr, JA Pieper Clinical pharmacology & therapeutics 63 (3), 316-323, 1998 | 113 | 1998 |
| Altered protein binding of etoposide in patients with cancer CF Stewart, JA Pieper, SG Arbuck, WE Evans Clinical Pharmacology & Therapeutics 45 (1), 49-55, 1989 | 105 | 1989 |
| Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety JA Pieper American journal of health-system pharmacy 60 (suppl_2), S9-S14, 2003 | 101 | 2003 |
| Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes CR Lee, JA Pieper, RF Frye, AL Hinderliter, JA Blaisdell, JA Goldstein European journal of clinical pharmacology 58, 791-794, 2003 | 96 | 2003 |
| Understanding niacin formulations. JA Pieper The American journal of managed care 8 (12 Suppl), S308-14, 2002 | 88 | 2002 |
| Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes CR Lee, JA Pieper, AL Hinderliter, JA Blaisdell, JA Goldstein Clinical Pharmacology & Therapeutics 72 (5), 562-571, 2002 | 80 | 2002 |
| Factors influencing serum protein binding of lidocaine in humans PJ McNamara, RL Slaughter, JA Pieper, MG Wyman, D Lalka Anesthesia & Analgesia 60 (6), 395-400, 1981 | 76 | 1981 |
| Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan JS McCune, C Lindley, JL Decker, KM Williamson, AM Meadowcroft, ... The Journal of Clinical Pharmacology 41 (7), 723-731, 2001 | 69 | 2001 |
| The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers AM Meadowcroft, KM Williamson, JH Patterson, AL Hinderliter, JA Pieper The Journal of Clinical Pharmacology 39 (4), 418-424, 1999 | 57 | 1999 |
| Losartan and E3174 Pharmacokinetics in Cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 Individuals CR Lee, JA Pieper, AL Hinderliter, JA Blaisdell, JA Goldstein Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 23 (6 …, 2003 | 56 | 2003 |
| Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients DW Graff, KM Williamson, JA Pieper, SW Carson, KF Adams Jr, ... The Journal of Clinical Pharmacology 41 (1), 97-106, 2001 | 55 | 2001 |
| Hepatic drug clearance in children: studies with indocyanine green as a model substrate WE Evans, MV Relling, S De Graaf, JH Rodman, JA Pieper, ... Journal of pharmaceutical sciences 78 (6), 452-456, 1989 | 53 | 1989 |
| Lidocaine JA Pieper, JH Rodman Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 2nd …, 1986 | 51 | 1986 |
| Evaluation of potential losartan‐phenytoin drug interactions in healthy volunteers TL Fischer, JA Pieper, DW Graff, JE Rodgers, JD Fischer, KJ Parnell, ... Clinical Pharmacology & Therapeutics 72 (3), 238-246, 2002 | 50 | 2002 |
| Effect of food on lidocaine kinetics: Mechanism of food‐related alteration in high intrinsic clearance drug elimination AT Elvin, AFD Cole, JA Pieper, SH Rolbin, D Lalka Clinical Pharmacology & Therapeutics 30 (4), 455-460, 1981 | 46 | 1981 |
